Sumitomo Pharma Beheer

Beheer criteriumcontroles 2/4

De CEO Sumitomo Pharma is Toru Kimura, benoemd in Jan2016, heeft een ambtstermijn van 8.83 jaar. bezit rechtstreeks 0.02% van de aandelen van het bedrijf, ter waarde ¥ 48.04M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 2.2 jaar en 3.9 jaar.

Belangrijke informatie

Toru Kimura

Algemeen directeur

n/a

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	8.8yrs
Eigendom CEO	0.02%
Management gemiddelde ambtstermijn	2.2yrs
Gemiddelde ambtstermijn bestuur	3.9yrs

Recente managementupdates

Recent updates

Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?

Nov 25

Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?

Sep 12

There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price Rise

Aug 16

A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price Climb

Jun 26

Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?

May 13

Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues

Apr 17

CEO

Toru Kimura (64 yo)

8.8yrs

Tenure

Mr. Toru Kimura, Ph D., is Representative Director, President & CEO of Sumitomo Pharma Co. Ltd. from June 25, 2024.Mr. Toru serves as Director at Sumitomo Pharma America, Inc. since 2024. He served as Rep...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Toru Kimura	Representative Director	8.8yrs	geen gegevens	0.020% ¥ 48.0m
Motoyuki Sakai	Representative Director and Executive VP of Corporate Planning	less than a year	geen gegevens	geen gegevens
Hiroyuki Baba	Mngg Exec. Officer of Global Data Design	7.6yrs	geen gegevens	0.0015% ¥ 3.7m
Naoki Noguchi	Executive Officer of Corporate Governance & Communications	2.6yrs	geen gegevens	geen gegevens
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	4.4yrs	geen gegevens	0.0038% ¥ 9.3m
Koichi Kozuki	E.O. of R. Aff.	1.8yrs	geen gegevens	geen gegevens
Shigeyuki Nishinaka	Managing Executive Office	7.6yrs	geen gegevens	0.0020% ¥ 4.9m
Isao Shimizu	Executive Officer	1.8yrs	geen gegevens	geen gegevens
Kenji Ueno	Executive Officer	1.8yrs	geen gegevens	geen gegevens
Hideyuki Harada	Managing Exe. Officer of Tech. R&D Div.	3.6yrs	geen gegevens	geen gegevens
Tsutomu Nakagawa	Executive Officer	1.8yrs	geen gegevens	0.00076% ¥ 1.9m
Yumi Sato	Exe Off of Drug Dev Div	1.8yrs	geen gegevens	geen gegevens

2.2yrs

Gemiddelde duur

64yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 4506 wordt beschouwd als ervaren (gemiddelde ambtstermijn 2.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Toru Kimura	Representative Director	8.4yrs	geen gegevens	0.020% ¥ 48.0m
Motoyuki Sakai	Representative Director and Executive VP of Corporate Planning	less than a year	geen gegevens	geen gegevens
Yoshiharu Ikeda	Managing Executive Officer of Drug Research Division	4.4yrs	geen gegevens	0.0038% ¥ 9.3m
Tsutomu Nakagawa	Executive Officer	less than a year	geen gegevens	0.00076% ¥ 1.9m
Saeko Arai	Independent Outside Director	6.4yrs	geen gegevens	geen gegevens
Minoru Usui	Independent Outside Director	3.4yrs	geen gegevens	geen gegevens
Nobuhiro Endo	Independent Outside Director	5.4yrs	geen gegevens	geen gegevens
Hiroshi Niinuma	Director	less than a year	geen gegevens	geen gegevens
Takashi Kutsunai	Full-Time Audit & Supervisory Board Member	6.4yrs	geen gegevens	0.0065% ¥ 16.0m
Yoshio Iteya	Outside Audit & Supervisory Board Member	6.4yrs	geen gegevens	geen gegevens
Hisayoshi Kashima	Full-Time Audit & Supervisory Board Member	1.4yrs	geen gegevens	0.0035% ¥ 8.6m
Koji Fujimoto	Independent Outside Director	2.4yrs	geen gegevens	geen gegevens

3.9yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 4506 wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.9 jaar).

Sumitomo Pharma Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Less than half of directors are independent

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Less than half of directors are independent

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 23, 2022

Recent updates

Sumitomo Pharma (TSE:4506) Has Debt But No Earnings; Should You Worry?

Sumitomo Pharma Co., Ltd. to Report Q3, 2025 Results on Jan 31, 2025

New major risk - Share price stability

Second quarter 2025 earnings: EPS misses analyst expectations

Consensus EPS estimates upgraded to JP¥25.34 loss

Sumitomo Pharma Co., Ltd.(TSE:4506) dropped from FTSE All-World Index (USD)

Is There An Opportunity With Sumitomo Pharma Co., Ltd.'s (TSE:4506) 38% Undervaluation?

There's No Escaping Sumitomo Pharma Co., Ltd.'s (TSE:4506) Muted Revenues Despite A 26% Share Price Rise

Consensus EPS estimates upgraded to JP¥39.20 loss

Price target increased by 14% to JP¥365

Sumitomo Pharma and Poxel Announce Topline Results from Post-Marketing Clinical Study on TWYMEEG for the Treatment of Type 2 Diabetes in Japan

Less than half of directors are independent

Sumitomo Pharma Co., Ltd. to Report Q2, 2025 Results on Oct 30, 2024

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Consensus EPS estimates upgraded to JP¥48.57 loss

A Piece Of The Puzzle Missing From Sumitomo Pharma Co., Ltd.'s (TSE:4506) 28% Share Price Climb

Consensus EPS estimates upgraded to JP¥77.85 loss

Consensus EPS estimates upgraded to JP¥103 loss

Sumitomo Pharma Co., Ltd. to Report Q1, 2025 Results on Jul 31, 2024

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 25, 2024

Full year 2024 earnings: EPS misses analyst expectations

Is Sumitomo Pharma Co., Ltd. (TSE:4506) Trading At A 34% Discount?

Price target decreased by 18% to JP¥334

Consensus EPS estimates fall by 21%

Market Cool On Sumitomo Pharma Co., Ltd.'s (TSE:4506) Revenues

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2024 Results on May 14, 2024

Price target decreased by 10% to JP¥413

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 24%

Consensus EPS estimates fall by 24%

Price target decreased by 7.8% to JP¥442

Consensus EPS estimates fall by 23%

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

New major risk - Share price stability

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024

Sumitomo Pharma Co., Ltd. to Report Q3, 2024 Results on Jan 31, 2024

European Commission Approves the Commercialisation of RYEQO® for the Symptomatic Treatment of Endometriosis

Gedeon Richter Plc., Sumitomo Pharma America, Inc. and Sumitomo Pharma Switzerland, GmbH Receives European Commission grant for Commercialisation of RYEQO®

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Sumitomo Pharma Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year of Fiscal Year Ending March 31, 2024

Price target decreased by 9.3% to JP¥510

Sumitomo Pharma Announces Positive Topline Results from Phase 3 Clinical Studies Evaluating Vibegron in Men with Overactive Bladder Symptoms Receiving Pharmacological Therapy for Benign Prostatic Hyperplasia

Consensus EPS estimates fall by 10%

Consensus EPS estimates fall by 15%

Price target decreased by 11% to JP¥630

Sumitomo Pharma Co., Ltd. to Report Q2, 2024 Results on Oct 31, 2023

Sumitomo Pharma Co., Ltd. (TSE:4506) acquired Assets and rights related lefamulin in China, Hong Kong, Macau and Taiwan from Nabriva Therapeutics plc (OTCPK:NBRV.F), Nabriva Therapeutics US, Inc, Nabriva Therapeutics GmbH and Nabriva Therapeutics Ireland Dac for $15 million.

First quarter 2024 earnings: EPS and revenues miss analyst expectations

New minor risk - Share price stability

Sumitomo Pharma and Otsuka Announce Topline Results from Phase 3 Diamond 1 and Diamond 2 Clinical Studies Evaluating Ulotaront in Schizophrenia

Consensus EPS estimates fall by 14%

Sumitomo Pharma Co., Ltd. Announces Executive Changes

Sumitomo Pharma Co., Ltd. to Report Q1, 2024 Results on Jul 31, 2023

Revolka Ltd. Announces Milestone Achievement in the Collaborative Research with Sumitomo Pharma Co., Ltd

HEALIOS K.K. and Sumitomo Pharma Co. Ltd. Announces Start of Phase 1/2 Study in RPE Tear Using RPE Cells Derived from Allogeneic iPS Cells (HLCR011)

Sumitomo Pharma Oncology, Inc. Presents Updated Preliminary Data from Phase 1/2 Clinical Study Evaluating Investigational Agent TP-3654 in Patients with Myelofibrosis at European Hematology Association 2023 Hybrid Congress

Consensus EPS estimates fall by 17%

Price target decreased by 10% to JP¥811

Price target decreased by 7.2% to JP¥883

Consensus EPS estimates fall by 26%, revenue upgraded

Sumitomo Pharma Co., Ltd. Announces Dividend for the Year Ended March 31, 2023, Payable on June 28, 2023

Full year 2023 earnings: EPS misses analyst expectations

Sumitomo Pharma Co., Ltd., Annual General Meeting, Jun 27, 2023

Consensus EPS estimates upgraded to JP¥35.42 loss

Consensus EPS estimates upgraded to JP¥35.42 loss

Upcoming dividend of JP¥7.00 per share at 3.5% yield

Consensus estimates of losses per share improve by 85%

Consensus EPS estimates have been downgraded.

Sumitomo Pharma Co., Ltd. to Report Fiscal Year 2023 Results on May 15, 2023